Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)

Inclusion Criteria * Age ≥ 18 years. * Subarachnoid hemorrhage secondary to ruptured aneurysm. * Ruptured aneurysm secured with surgical clipping or endovascular intervention. * Digital subtraction angiography (DSA) or CT angiography at the time of aSAH clinical presentation or aSAH intervention with well-visualized intra-cerebral vessels is available for review. * Vasospasm in one or more of the following: the internal carotid artery (ICA), basilar, middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA) territory on transcranial Doppler (TCD), and/or CT angiography, and/or clinical signs of symptomatic vasospasm (change in level of consciousness, focal neurological deficit) confirmed by \> 50% narrowing in these territories on DSA. * Vasospasm despite maximized medical management defined as oral Nimodipine (unless contraindicated), systemic hypertension with SBP greater than 130 mmHg and euvolemia. * Target vessel pre-vasospasm diameter ≥ 2 mm and ≤ 4.0 mm. * Subject or legal representative is able and willing to give informed consent. Exclusion Criteria * The presence of an unsecured ruptured aneurysm. Note unsecured unruptured aneurysms remote to the site of treated aSAH are not an exclusionary. * Symptoms attributable to other causes (e.g., hydrocephalus, metabolic, infection). * Hunt and Hess Grade of 5 * Large infarct on CT scan defined as ASPECTS 0-5. * Intracranial hemorrhage not caused by aneurysm rupture. * History of bleeding disorders. * Baseline platelets \< 30,000. * International normalized ratio (INR) \> 1.7. * Any known contraindications to mechanical dilation of vasospastic vessels including but not limited to: * Excessive vessel tortuosity that prevents the placement of the device * Evidence of rapidly improving neurological signs of stroke * Large territory completed cerebral infarction, edema with mass effect and intra-parenchymal hemorrhage in vascular territory to be treated, or * any other vascular anatomic variants or anomalies * Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept). * History of severe allergy to contrast medium. * Known allergy to NeVa materials (nitinol, stainless steel). * Suspected or confirmed septic embolus, or bacterial endocarditis. * Septic shock or central nervous system (CNS) infection confirmed via cerebrospinal fluid (CSF) sampling. * Known current or recent use of illicit drugs or alcohol abuse. * Females who are pregnant or breastfeeding. * Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure is performed.